| 13.37 0.35 (2.69%) | 10-08 13:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.77  |
1-year : | 20.76 |
| Resists | First : | 15.22 |
Second : | 17.77 |
| Pivot price | 13.03 |
|||
| Supports | First : | 12.66 |
Second : | 11.09 |
| MAs | MA(5) : | 13.8 |
MA(20) : | 12.97 |
| MA(100) : | 13.67 |
MA(250) : | 8.63 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 45.2 |
D(3) : | 58 |
| RSI | RSI(14): 52 |
|||
| 52-week | High : | 23.86 | Low : | 3.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed below upper band by 42.0%. Bollinger Bands are 52% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.79 - 13.9 | 13.9 - 13.97 |
| Low: | 12.61 - 12.73 | 12.73 - 12.81 |
| Close: | 12.86 - 13.05 | 13.05 - 13.17 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Mon, 07 Oct 2024
Is Novavax, Inc. (NVAX) the Best High-Flying Stock to Buy? - Yahoo Finance
Sun, 06 Oct 2024
98,777 Shares in Novavax, Inc. (NASDAQ:NVAX) Acquired by Squarepoint Ops LLC - MarketBeat
Sat, 05 Oct 2024
Novavax, Inc. (NASDAQ:NVAX) Stock Holdings Increased by SG Americas Securities LLC - MarketBeat
Thu, 03 Oct 2024
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Thu, 03 Oct 2024
Novavax: Lack Of Sustainable Revenue Growth Is A Problem (NASDAQ:NVAX) - Seeking Alpha
Thu, 03 Oct 2024
Novavax stock falls after comments on report (NASDAQ:NVAX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 160 (M) |
| Shares Float | 143 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 54.3 (%) |
| Shares Short | 33,530 (K) |
| Shares Short P.Month | 30,500 (K) |
| EPS | -2.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.71 |
| Profit Margin | -29.8 % |
| Operating Margin | 39 % |
| Return on Assets (ttm) | -10.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -2.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 6.16 |
| EBITDA (p.s.) | -1.51 |
| Qtrly Earnings Growth | 70.9 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | -98 (M) |
| PE Ratio | -5.07 |
| PEG Ratio | -0.5 |
| Price to Book value | -4.92 |
| Price to Sales | 2.15 |
| Price to Cash Flow | 148.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|